MedPath

Nabilone

Generic Name
Nabilone
Brand Names
Cesamet
Drug Type
Small Molecule
Chemical Formula
C24H36O3
CAS Number
51022-71-0
Unique Ingredient Identifier
2N4O9L084N
Background

Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments .

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Nabilone or Dronabinol), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.

From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function .

In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.

Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.

Indication

Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents.

Associated Conditions
Refractory Chemotherapy-Induced Nausea and Vomiting (CINV)
Associated Therapies
-

Nabilone for Agitation in Frontotemporal Dementia

Phase 2
Active, not recruiting
Conditions
Frontotemporal Dementia
FTD
Frontotemporal Dementia, Behavioral Variant
bvFTD
PPA
Primary Progressive Aphasia
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2023-02-24
Last Posted Date
2023-10-13
Lead Sponsor
Simon Ducharme, MD
Target Recruit Count
45
Registration Number
NCT05742698
Locations
🇨🇦

University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada

🇨🇦

Western Hospital - University of Toronto, Toronto, Ontario, Canada

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 4 locations

Effect of PP-01 on Cannabis Withdrawal Syndrome

Phase 2
Completed
Conditions
Cannabis Withdrawal
Interventions
Combination Product: PP-01 High Dose
Combination Product: PP-01 Low Dose
Drug: Placebo
Drug: Nabilone
Drug: Gabapentin
First Posted Date
2022-08-10
Last Posted Date
2024-08-16
Lead Sponsor
PleoPharma, Inc.
Target Recruit Count
234
Registration Number
NCT05494437
Locations
🇺🇸

Pahl Pharmaceutical Professionals LLC, Oklahoma City, Oklahoma, United States

🇺🇸

Pillar Clinical Research, LLC, Chicago, Illinois, United States

🇺🇸

Behavioral Research Specialists, LLC, Glendale, California, United States

and more 15 locations

Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

Phase 1
Recruiting
Conditions
Behavior Problem
Intellectual Disability
Developmental Disability
Aggression
Interventions
First Posted Date
2022-03-10
Last Posted Date
2024-01-10
Lead Sponsor
Hsiang-Yuan Lin
Target Recruit Count
30
Registration Number
NCT05273320
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Phase 1
Withdrawn
Conditions
Obsessive-Compulsive Disorder
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2021-05-10
Last Posted Date
2024-05-21
Lead Sponsor
New York State Psychiatric Institute
Registration Number
NCT04880278
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Phase 2
Withdrawn
Conditions
Suicidal Ideation
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2021-03-19
Last Posted Date
2021-09-22
Lead Sponsor
The University of Texas Health Science Center, Houston
Registration Number
NCT04807829
Locations
🇺🇸

Harris County Psychiatric Center (HCPC), Houston, Texas, United States

A Pilot Trial of Nabilone for the Treatment of Obesity

Phase 2
Terminated
Conditions
Obesity
Interventions
Drug: Placebo
Drug: Nabilone
First Posted Date
2021-03-17
Last Posted Date
2024-01-29
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
24
Registration Number
NCT04801641
Locations
🇨🇦

Center for Addiction and Mental Health, Toronto, Ontario, Canada

Nabilone for Agitation Blinded Intervention Trial

Phase 3
Recruiting
Conditions
Alzheimer Disease
Agitation
Interventions
Other: Placebo
Drug: Nabilone
First Posted Date
2020-08-17
Last Posted Date
2024-12-24
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
112
Registration Number
NCT04516057
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇨🇦

University of Calgary, Calgary, Alberta, Canada

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 2 locations

Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

Not Applicable
Not yet recruiting
Conditions
Inflammatory Bowel Diseases
Interventions
Drug: Placebos
Drug: Nabilone
First Posted Date
2018-02-06
Last Posted Date
2023-06-07
Lead Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Target Recruit Count
80
Registration Number
NCT03422861
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Nabilone in Cannabis Users With PTSD

Phase 1
Terminated
Conditions
Cannabis
Post Traumatic Stress Disorder
Interventions
First Posted Date
2017-08-16
Last Posted Date
2022-07-15
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
4
Registration Number
NCT03251326
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

Completed
Conditions
FBSS
Interventions
Drug: Nabilone
Drug: THC/CBD
First Posted Date
2017-07-07
Last Posted Date
2019-01-16
Lead Sponsor
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Target Recruit Count
20
Registration Number
NCT03210766
© Copyright 2025. All Rights Reserved by MedPath